Plain-English translation of NCT07020117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called [225Ac]Ac-AKY-1189, which is a radioactive treatment designed to find and destroy cancer cells in several types of advanced solid tumors. The study has two parts: first, researchers will test different doses to find the safest and most effective amount, and then they will give the medication to more patients to see how well it works.
Many patients with advanced cancers have limited treatment options after their cancer stops responding to standard therapies. This medication is designed to target cancer cells more precisely using radioactive particles, potentially offering a new hope for patients whose cancers have already progressed on other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication over multiple treatment cycles (up to 6 cycles in the first part of the study). Throughout the trial, you would have regular clinic visits for monitoring, blood tests, and imaging scans to check how your cancer is responding. The study is being conducted at multiple centers, and your participation would involve close medical supervision to ensure your safety and assess how well the treatment is working.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States